Wosulin-N 40IU/ml Suspension for Injection contains Insulin Isophane (40IU), an intermediate-acting insulin used for the management of diabetes mellitus. This formulation provides a prolonged duration of action, facilitating improved glycemic control by mimicking the basal insulin secretion in patients with type 1 and type 2 diabetes. Wosulin-N is indicated for subcutaneous administration to regulate blood glucose levels, either as monotherapy or in combination with short-acting insulins or oral hypoglycemic agents. The suspension should be gently mixed before use to ensure uniform distribution of insulin particles. Onset of action typically occurs within 1 to 2 hours post-injection, with peak activity between 4 to 12 hours and a duration of up to 24 hours, allowing for once or twice-daily dosing depending on individual patient requirements. Dose titration must be individualized based on blood glucose monitoring to minimize the risk of hypoglycemia. Caution is advised in patients with renal or hepatic impairment, and during periods of stress or illness, as insulin requirements may vary. Proper storage conditions must be maintained to preserve potency. Wosulin-N should be administered under medical supervision with regular monitoring to optimize therapeutic outcomes and ensure patient safety.